Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Manufacturing

USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns

 April 13, 2026

BioSpace

Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S.

ManufacturingRead full story

Post navigation

Allogene stock sails after CAR T clears residual lymphoma in early data cut →
← FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com